etamicastat
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT02845037)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Dopamine beta-hydroxylaseINHIBITOR
DBH inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione
- 5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione hydrochloride
- bia 5-453
- bia 5-453
- bia 5-453
- bia-5-453
- bia-5-453
- bia-5-453
- etamicastat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03014375 | Phase 1 | Sep 1, 2008 | Bial |
| NCT03090568 | Phase 1 | Jul 15, 2008 | Bial |
| NCT03099226 | Phase 1 | Jul 15, 2008 | Bial |
| NCT03090724 | Phase 1 | Jun 13, 2008 | Bial |
| NCT02840565 | Phase 1 | Sep 1, 2007 | Bial |
| NCT02845037 | Phase 1 | May 1, 2007 | Bial |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bial | For profit | 6 | 6 | 1 | 2007 |
1 organizations
Page 1 / 1